Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
OBJECTIVE
To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH).


METHODS
Prospective randomized clinical study.


METHODS
Social Security Agency, Aegean Obstetrics and Gynecology Teaching Hospital, Department of Reproductive Endocrinology and Infertility, a tertiary referral center.


METHODS
Eighty women with IH who had been admitted to our center.


METHODS
Patients were randomly and equally assigned to receive flutamide (250 mg/d for the first 10 days of the cycle) and spironolactone plus Diane 35 (spironolactone 100 mg/d; Diane 35 is a combination tablet of 2 mg cyproterone acetate and 35 microg ethinylestradiol/d) for 9 months.


METHODS
Modified Ferriman-Gallwey (F-G) score and hormonal profile before treatment and at the end of treatment.


RESULTS
In spite of the fact that there were no statistically significant differences in modified F-G scores in between the two groups, a significant decrease in modified F-G scores was observed in the flutamide (from 19.93 +/- 4.31 to 15.58 +/- 4.28) and spironolactone plus Diane 35 (from 18.77 +/- 3.76 to 14.54 +/- 3.29) groups. There were also no differences between the two groups with respect to hormonal profiles including serum FSH, LH, free T, 17-OH-progesterone, and DHEAS levels. No major side effect, including liver toxicity, was observed in either group.


CONCLUSIONS
Our data suggest that both therapies have similar effectiveness in the treatment of IH.
Inal
M Murat
MM
Social Security Agency, Department of Reproductive Endocrinology and Infertility, Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey.
Yildirim
Yusuf
Y
Taner
C Eftal
CE
D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage*; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D004232:Diuretics / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D005485:Flutamide / Q000008:administration & dosage*; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011446:Prospective Studies; D013148:Spironolactone / Q000008:administration & dosage*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D004232:Diuretics; D004338:Drug Combinations; D013148:Spironolactone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D005485:Flutamide